Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Kerecis

Explore full profile

Develops, manufactures, and markets implants and repair materials for the human body from omega3 rich fish skin

Ísafjörður, IcelandFounded 2010Biotech & Life Sciences
Valuation $1–2.5B Last recorded · 2023
Revenue $100–500M Latest reported FY
Headcount 500–1k Current team size
Total funding $100–500M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Kerecis and the history behind them.

About Kerecis

Kerecis is a pioneering startup that operates in the healthcare sector, specifically in wound care. The company has developed an innovative solution for treating complex wounds, burns, and other acute and chronic wounds, including those resulting from diabetes, venous issues, trauma, and surgery. The treatment involves the use of intact fish skin, sourced from wild Atlantic cod caught in the pristine waters of Iceland. This fish skin is processed using renewable energy, underscoring the company's commitment to sustainability.

Read full description

The company's primary clients are patients suffering from stubborn wounds that are not healing properly. Kerecis has successfully treated thousands of patients across different income levels, cultures, and races, demonstrating the broad applicability and effectiveness of its solution. The story of Alana Smith, a real estate agent from Palo Alto, California, who was at risk of losing a limb due to a stubborn wound, is a testament to the company's impact. With Kerecis' treatment, her wound healed, saving her limb.

Kerecis operates in the global wound care market, which is a growing sector due to the increasing prevalence of chronic diseases such as diabetes. The company's business model involves the sale of its fish-skin treatment to healthcare providers, who then administer it to patients. This approach allows Kerecis to generate revenue while providing a much-needed solution to a pressing healthcare issue.

Source: Dealroom company data

At a glance

Founded
2010
Headquarters
Ísafjörður, Iceland
Sector
Biotech & Life Sciences
Power Law
Unicorn$1–10B valuation tier

Latest news

Press, funding announcements and product moves mentioning Kerecis.

See all news

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Icelandic Centre for Research

Series B and later5 investors entered at this stage

Employees mapped 525 incl. 1 AI specialist
Founders Hidden — book a demo/100 quality score
Key operators 28 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
11 countries with
team presence
🇺🇸 United States79.2%
🇮🇸 Iceland15.7%
🇩🇪 Germany1.3%
🇨🇭 Switzerland1.1%
🇩🇰 Denmark0.7%
Top 5 of 11 shown
Web traffic by country
27K monthly visits
across markets
🇮🇳 India59.3%
🇺🇸 United States20.4%
🇩🇰 Denmark7%
🇬🇧 United Kingdom5.9%
🇻🇳 Vietnam3%
Top 5 markets shown

Patents

Estimated portfolio value
$11M

13 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Kerecis on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Kerecis on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.